| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Lymphocytic, Chronic, B-Cell | 16 | 2024 | 44 | 4.390 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 6 | 2024 | 50 | 2.280 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2024 | 140 | 1.820 |
Why?
|
| DNA-Binding Proteins | 8 | 2008 | 491 | 1.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2024 | 156 | 0.930 |
Why?
|
| Apoptosis | 8 | 2016 | 774 | 0.830 |
Why?
|
| Cicatrix | 1 | 2023 | 14 | 0.820 |
Why?
|
| Burns | 1 | 2023 | 17 | 0.810 |
Why?
|
| Signal Transduction | 4 | 2021 | 1433 | 0.810 |
Why?
|
| Transcription Factors | 6 | 2006 | 522 | 0.790 |
Why?
|
| Sirtuin 3 | 1 | 2021 | 18 | 0.720 |
Why?
|
| Catalase | 1 | 2021 | 48 | 0.710 |
Why?
|
| Reactive Oxygen Species | 1 | 2021 | 284 | 0.630 |
Why?
|
| Prostatic Neoplasms | 3 | 2006 | 277 | 0.580 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2010 | 179 | 0.520 |
Why?
|
| Humans | 34 | 2025 | 28166 | 0.510 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2015 | 97 | 0.500 |
Why?
|
| Antineoplastic Agents | 5 | 2021 | 678 | 0.500 |
Why?
|
| Catechin | 3 | 2012 | 13 | 0.490 |
Why?
|
| Genetic Therapy | 2 | 2006 | 123 | 0.460 |
Why?
|
| Sulfonamides | 1 | 2015 | 73 | 0.450 |
Why?
|
| Pyrimidines | 1 | 2015 | 126 | 0.430 |
Why?
|
| B-Lymphocytes | 5 | 2015 | 284 | 0.400 |
Why?
|
| RNA Interference | 4 | 2009 | 137 | 0.390 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 2 | 2009 | 12 | 0.390 |
Why?
|
| Tumor Cells, Cultured | 8 | 2021 | 315 | 0.380 |
Why?
|
| Viral Nonstructural Proteins | 5 | 2004 | 12 | 0.370 |
Why?
|
| Coculture Techniques | 6 | 2024 | 55 | 0.350 |
Why?
|
| Up-Regulation | 3 | 2021 | 245 | 0.350 |
Why?
|
| Cell Proliferation | 4 | 2008 | 806 | 0.340 |
Why?
|
| Cell-Derived Microparticles | 1 | 2009 | 11 | 0.330 |
Why?
|
| Bone Marrow Cells | 1 | 2009 | 80 | 0.320 |
Why?
|
| Disease Progression | 5 | 2024 | 474 | 0.320 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2009 | 11 | 0.310 |
Why?
|
| MicroRNAs | 2 | 2013 | 299 | 0.310 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2008 | 29 | 0.300 |
Why?
|
| Membrane Transport Proteins | 2 | 2006 | 78 | 0.300 |
Why?
|
| Curcumin | 1 | 2009 | 69 | 0.290 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2008 | 103 | 0.290 |
Why?
|
| Fibroblasts | 1 | 2008 | 155 | 0.280 |
Why?
|
| Cellular Senescence | 1 | 2008 | 125 | 0.280 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2016 | 465 | 0.280 |
Why?
|
| Stromal Cells | 4 | 2016 | 61 | 0.270 |
Why?
|
| Cells, Cultured | 5 | 2021 | 985 | 0.270 |
Why?
|
| Cell Line, Tumor | 8 | 2024 | 1327 | 0.270 |
Why?
|
| Caregivers | 2 | 2025 | 121 | 0.260 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2021 | 10 | 0.260 |
Why?
|
| Growth Inhibitors | 1 | 2006 | 11 | 0.260 |
Why?
|
| beta Catenin | 2 | 2021 | 66 | 0.250 |
Why?
|
| Male | 15 | 2025 | 13510 | 0.250 |
Why?
|
| Homeodomain Proteins | 2 | 2003 | 79 | 0.240 |
Why?
|
| Cell Cycle | 1 | 2006 | 161 | 0.240 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2025 | 9 | 0.240 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2006 | 105 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2016 | 68 | 0.240 |
Why?
|
| Repressor Proteins | 1 | 2006 | 118 | 0.240 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2005 | 4 | 0.240 |
Why?
|
| Nerve Tissue Proteins | 1 | 2006 | 153 | 0.240 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 411 | 0.230 |
Why?
|
| Health Literacy | 1 | 2025 | 34 | 0.230 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2005 | 50 | 0.230 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2005 | 87 | 0.230 |
Why?
|
| Bangladesh | 1 | 2024 | 14 | 0.230 |
Why?
|
| Transcription, Genetic | 2 | 2003 | 402 | 0.230 |
Why?
|
| MAP Kinase Signaling System | 1 | 2005 | 95 | 0.220 |
Why?
|
| Cerebral Palsy | 1 | 2024 | 31 | 0.220 |
Why?
|
| Extracellular Vesicles | 1 | 2024 | 42 | 0.210 |
Why?
|
| Luteinizing Hormone, beta Subunit | 1 | 2003 | 1 | 0.210 |
Why?
|
| Skin Transplantation | 1 | 2023 | 15 | 0.200 |
Why?
|
| Interferon-alpha | 1 | 2003 | 50 | 0.200 |
Why?
|
| Lung Neoplasms | 1 | 2006 | 356 | 0.200 |
Why?
|
| Gene Silencing | 2 | 2021 | 65 | 0.200 |
Why?
|
| Quinazolinones | 1 | 2022 | 5 | 0.200 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2024 | 164 | 0.200 |
Why?
|
| Gene Expression Regulation | 2 | 2003 | 633 | 0.200 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 15 | 0.190 |
Why?
|
| Purines | 1 | 2022 | 17 | 0.190 |
Why?
|
| Cytochrome c Group | 1 | 2002 | 10 | 0.190 |
Why?
|
| Skin | 1 | 2023 | 149 | 0.190 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2015 | 157 | 0.190 |
Why?
|
| Transfection | 3 | 2015 | 318 | 0.180 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 2021 | 0.170 |
Why?
|
| NF-kappa B | 3 | 2009 | 191 | 0.170 |
Why?
|
| Cell Line | 3 | 2009 | 694 | 0.170 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2010 | 6 | 0.170 |
Why?
|
| STAT3 Transcription Factor | 3 | 2009 | 98 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 167 | 0.160 |
Why?
|
| Hepacivirus | 3 | 2004 | 48 | 0.150 |
Why?
|
| Mitochondria | 1 | 2002 | 366 | 0.150 |
Why?
|
| Drug Synergism | 2 | 2016 | 104 | 0.150 |
Why?
|
| Aged | 6 | 2021 | 5416 | 0.150 |
Why?
|
| Adult | 6 | 2025 | 7765 | 0.140 |
Why?
|
| Female | 10 | 2025 | 15191 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 3 | 2003 | 345 | 0.130 |
Why?
|
| Middle Aged | 6 | 2021 | 7164 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 3 | 2006 | 276 | 0.130 |
Why?
|
| Binding Sites | 2 | 2010 | 354 | 0.130 |
Why?
|
| Organometallic Compounds | 1 | 2016 | 41 | 0.120 |
Why?
|
| Enzyme Activation | 3 | 2009 | 267 | 0.120 |
Why?
|
| RNA, Small Interfering | 2 | 2008 | 198 | 0.120 |
Why?
|
| Mice, Nude | 2 | 2006 | 330 | 0.120 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 68 | 0.120 |
Why?
|
| Protein Binding | 2 | 2009 | 657 | 0.110 |
Why?
|
| Flow Cytometry | 1 | 2015 | 288 | 0.110 |
Why?
|
| Mice | 6 | 2006 | 4655 | 0.110 |
Why?
|
| Lymphocytosis | 1 | 2013 | 2 | 0.110 |
Why?
|
| Paired Box Transcription Factors | 2 | 2003 | 3 | 0.100 |
Why?
|
| Blotting, Western | 1 | 2015 | 513 | 0.100 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2013 | 8 | 0.100 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2013 | 35 | 0.100 |
Why?
|
| Asymptomatic Diseases | 1 | 2012 | 17 | 0.100 |
Why?
|
| Cell Survival | 2 | 2016 | 408 | 0.100 |
Why?
|
| Liver | 3 | 2003 | 441 | 0.090 |
Why?
|
| Phosphorylation | 2 | 2010 | 578 | 0.090 |
Why?
|
| Benzocycloheptenes | 1 | 2010 | 1 | 0.090 |
Why?
|
| Triazoles | 1 | 2010 | 16 | 0.090 |
Why?
|
| Nitriles | 1 | 2010 | 33 | 0.090 |
Why?
|
| Cell Nucleus | 2 | 2009 | 138 | 0.090 |
Why?
|
| Aniline Compounds | 1 | 2010 | 23 | 0.090 |
Why?
|
| Quinolines | 1 | 2010 | 25 | 0.090 |
Why?
|
| src-Family Kinases | 1 | 2010 | 71 | 0.090 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2009 | 8 | 0.080 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2009 | 42 | 0.080 |
Why?
|
| Butyrate Response Factor 1 | 1 | 2009 | 6 | 0.080 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2009 | 31 | 0.080 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2009 | 82 | 0.080 |
Why?
|
| Protein Kinases | 1 | 2010 | 158 | 0.080 |
Why?
|
| Animals | 6 | 2006 | 10416 | 0.080 |
Why?
|
| Hydroxylation | 1 | 2009 | 9 | 0.080 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 60 | 0.080 |
Why?
|
| Anticarcinogenic Agents | 1 | 2009 | 16 | 0.080 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2009 | 14 | 0.080 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2009 | 3 | 0.080 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2009 | 82 | 0.080 |
Why?
|
| Mixed Function Oxygenases | 1 | 2009 | 19 | 0.080 |
Why?
|
| Gene Expression | 3 | 2013 | 416 | 0.080 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2009 | 79 | 0.080 |
Why?
|
| Foreskin | 1 | 2008 | 4 | 0.080 |
Why?
|
| G1 Phase | 1 | 2008 | 17 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 329 | 0.080 |
Why?
|
| Hypoxia | 1 | 2009 | 89 | 0.080 |
Why?
|
| Lymphocyte Activation | 1 | 2009 | 208 | 0.070 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2009 | 102 | 0.070 |
Why?
|
| Cell Culture Techniques | 1 | 2009 | 116 | 0.070 |
Why?
|
| Child | 2 | 2025 | 2253 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 166 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2009 | 281 | 0.070 |
Why?
|
| Biomarkers, Tumor | 2 | 2013 | 406 | 0.070 |
Why?
|
| Transplantation, Heterologous | 1 | 2006 | 61 | 0.070 |
Why?
|
| Cell Membrane Permeability | 1 | 2006 | 44 | 0.070 |
Why?
|
| Cell Division | 1 | 2006 | 154 | 0.070 |
Why?
|
| Necrosis | 1 | 2006 | 84 | 0.060 |
Why?
|
| Cyclin A | 1 | 2006 | 2 | 0.060 |
Why?
|
| Myelin Basic Protein | 1 | 2006 | 4 | 0.060 |
Why?
|
| Cyclin B1 | 1 | 2006 | 7 | 0.060 |
Why?
|
| Cyclin B | 1 | 2006 | 9 | 0.060 |
Why?
|
| Microscopy, Confocal | 1 | 2006 | 113 | 0.060 |
Why?
|
| Cell Death | 1 | 2006 | 118 | 0.060 |
Why?
|
| Cell Size | 1 | 2006 | 24 | 0.060 |
Why?
|
| MAP Kinase Kinase 5 | 1 | 2005 | 1 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2005 | 5 | 0.060 |
Why?
|
| India | 1 | 2025 | 143 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2013 | 2383 | 0.060 |
Why?
|
| Neoplasm Staging | 3 | 2012 | 478 | 0.060 |
Why?
|
| Adenoviridae | 1 | 2005 | 67 | 0.060 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2005 | 80 | 0.060 |
Why?
|
| Anoikis | 1 | 2004 | 3 | 0.060 |
Why?
|
| Ebolavirus | 1 | 2004 | 8 | 0.060 |
Why?
|
| Viral Matrix Proteins | 1 | 2004 | 6 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 284 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2024 | 46 | 0.060 |
Why?
|
| Keratinocytes | 1 | 2024 | 33 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2025 | 274 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2002 | 248 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2005 | 270 | 0.050 |
Why?
|
| Developing Countries | 1 | 2024 | 50 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2024 | 66 | 0.050 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2003 | 12 | 0.050 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2006 | 298 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2004 | 118 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2005 | 202 | 0.050 |
Why?
|
| Fushi Tarazu Transcription Factors | 1 | 2003 | 1 | 0.050 |
Why?
|
| Steroidogenic Factor 1 | 1 | 2003 | 3 | 0.050 |
Why?
|
| Movement | 1 | 2024 | 98 | 0.050 |
Why?
|
| Leishmaniasis, Visceral | 1 | 2003 | 8 | 0.050 |
Why?
|
| Pituitary Gland | 1 | 2003 | 53 | 0.050 |
Why?
|
| Newcastle disease virus | 1 | 2003 | 1 | 0.050 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2003 | 2 | 0.050 |
Why?
|
| Leishmania donovani | 1 | 2003 | 9 | 0.050 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 24 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2003 | 47 | 0.050 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2003 | 32 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 145 | 0.050 |
Why?
|
| Coronary Vessels | 1 | 2004 | 152 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2003 | 86 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2003 | 112 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2003 | 137 | 0.050 |
Why?
|
| Spleen | 1 | 2003 | 112 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2025 | 775 | 0.050 |
Why?
|
| Viral Core Proteins | 1 | 2002 | 8 | 0.050 |
Why?
|
| Caspase 9 | 1 | 2002 | 16 | 0.050 |
Why?
|
| Enzyme Precursors | 1 | 2002 | 16 | 0.050 |
Why?
|
| Genome, Viral | 1 | 2002 | 31 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2024 | 153 | 0.050 |
Why?
|
| 3T3 Cells | 1 | 2002 | 46 | 0.050 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2002 | 2 | 0.050 |
Why?
|
| Caspases | 1 | 2002 | 42 | 0.050 |
Why?
|
| Caspase 3 | 1 | 2002 | 58 | 0.050 |
Why?
|
| fas Receptor | 1 | 2002 | 20 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2002 | 22 | 0.050 |
Why?
|
| bcl-X Protein | 1 | 2002 | 35 | 0.050 |
Why?
|
| Time Factors | 1 | 2006 | 1593 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 969 | 0.050 |
Why?
|
| HeLa Cells | 1 | 2002 | 208 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2025 | 1149 | 0.050 |
Why?
|
| Antibodies | 1 | 2002 | 124 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 969 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2002 | 233 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2002 | 243 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2004 | 362 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2002 | 162 | 0.040 |
Why?
|
| Infant | 1 | 2024 | 1014 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2012 | 190 | 0.040 |
Why?
|
| Adolescent | 1 | 2025 | 3128 | 0.040 |
Why?
|
| Ribosomal Protein S6 | 1 | 2016 | 1 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 608 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2013 | 75 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 194 | 0.030 |
Why?
|
| Microvessels | 1 | 2013 | 87 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 300 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 327 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2012 | 15 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 224 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 238 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2003 | 509 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 803 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2013 | 889 | 0.020 |
Why?
|
| Quinazolines | 1 | 2010 | 32 | 0.020 |
Why?
|
| Pyrroles | 1 | 2010 | 36 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2010 | 103 | 0.020 |
Why?
|
| Indoles | 1 | 2010 | 99 | 0.020 |
Why?
|
| Receptors, Transferrin | 1 | 2009 | 18 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 144 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2009 | 44 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2009 | 60 | 0.020 |
Why?
|
| Tea | 1 | 2009 | 7 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2009 | 198 | 0.020 |
Why?
|
| Cell Communication | 1 | 2009 | 68 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2009 | 140 | 0.020 |
Why?
|
| Patient Selection | 1 | 2009 | 148 | 0.020 |
Why?
|
| Oxygen | 1 | 2009 | 234 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2009 | 658 | 0.020 |
Why?
|
| Models, Biological | 1 | 2009 | 465 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2009 | 407 | 0.020 |
Why?
|
| Janus Kinase 1 | 1 | 2004 | 4 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 2004 | 27 | 0.010 |
Why?
|
| Genes, Viral | 1 | 2003 | 10 | 0.010 |
Why?
|
| Cystitis | 1 | 2003 | 11 | 0.010 |
Why?
|
| Hepatitis C, Chronic | 1 | 2004 | 32 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2003 | 82 | 0.010 |
Why?
|
| Carcinogens | 1 | 2003 | 39 | 0.010 |
Why?
|
| Transgenes | 1 | 2003 | 63 | 0.010 |
Why?
|
| Hepatomegaly | 1 | 2003 | 2 | 0.010 |
Why?
|
| Virus Replication | 1 | 2003 | 64 | 0.010 |
Why?
|
| Splenomegaly | 1 | 2003 | 10 | 0.010 |
Why?
|
| Liver Diseases | 1 | 2003 | 52 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2003 | 34 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2003 | 40 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2003 | 68 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2003 | 82 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2004 | 131 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 463 | 0.010 |
Why?
|
| Asparagine | 1 | 2002 | 8 | 0.010 |
Why?
|
| Threonine | 1 | 2002 | 20 | 0.010 |
Why?
|
| TNF Receptor-Associated Death Domain Protein | 1 | 2002 | 3 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2002 | 132 | 0.010 |
Why?
|
| Fas-Associated Death Domain Protein | 1 | 2002 | 3 | 0.010 |
Why?
|
| TNF Receptor-Associated Factor 1 | 1 | 2002 | 5 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2002 | 103 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2002 | 132 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2003 | 152 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2002 | 111 | 0.010 |
Why?
|
| Heart | 1 | 2003 | 223 | 0.010 |
Why?
|
| Genotype | 1 | 2002 | 457 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 690 | 0.010 |
Why?
|
| Cytokines | 1 | 2003 | 446 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 1052 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2002 | 252 | 0.010 |
Why?
|
| Peptides | 1 | 2002 | 289 | 0.010 |
Why?
|
| Proteins | 1 | 2002 | 252 | 0.010 |
Why?
|
| Neoplasms | 1 | 2003 | 818 | 0.010 |
Why?
|